Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Kazia Therapeutics Ltd (KZIA) is the issuer in a reported beneficial-ownership position attributed to ADAR1 Capital Management, LLC and its sole manager, Daniel Schneeberger. Each reporting person lists 967,740 American Depositary Shares (ADSs), or 6.2%, with shared voting and dispositive power; the ADSs are held directly by private investment funds managed by ADAR1. The position is as of September 30, 2026.
Those funds also hold warrants exercisable for 1,615,705 ADSs, which are excluded from reported ownership because the warrants are subject to a 4.99% beneficial ownership limitation. The 6.2% figure uses 15,548,878 ADSs outstanding, as referenced in the issuer’s prospectus supplement dated August 28, 2026; each ADS represents 500 ordinary shares.
Key Figures
Beneficially owned ADSs:967,740 ADSsOwnership percentage:6.2%ADSs underlying warrants:1,615,705 ADSs+3 more
6 metrics
Beneficially owned ADSs967,740 ADSsReported by each reporting person with shared voting and dispositive power.
Ownership percentage6.2%Based on 15,548,878 ADSs outstanding.
ADSs underlying warrants1,615,705 ADSsSeries A and Series B warrants held by funds managed by ADAR1; excluded from reported ownership.
Beneficial ownership limitation4.99%Applies to the warrants and ADSs issuable upon exercise.
ADSs outstanding15,548,878 ADSsBasis for the reported ownership percentage, as referenced in the prospectus supplement dated August 28, 2026.
Ordinary shares per ADS500 ordinary sharesEach American Depositary Share represents this number of ordinary shares.
Key Terms
American Depositary Shares, beneficial ownership limitations, shared voting power, shared dispositive power, +1 more
5 terms
American Depositary Sharestechnical
"American Depositary Shares, each representing five-hundred Ordinary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
beneficial ownership limitationsfinancial
"warrants are subject to 4.99% beneficial ownership limitations"
Beneficial ownership limitations are rules or contractual caps that restrict how much of a company’s stock an individual or entity can be treated as owning or controlling for legal, regulatory or corporate-governance purposes. They matter to investors because such limits affect voting power, reporting obligations, takeover risk and the ability to increase a stake — like an elevator weight limit or a lane divider that prevents any one car from taking over the whole road.
shared voting powertechnical
"Shared Voting Power 967,740.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powertechnical
"Shared Dispositive Power 967,740.00"
Series A and Series B warrantsfinancial
"hold Series A and Series B warrants exercisable for 1,615,705 Depositary Shares"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many KZIA ADSs did ADAR1 and Daniel Schneeberger report?
Each reported beneficial ownership of 967,740 ADSs, or 6.2%, with shared voting and dispositive power; the ADSs are directly owned by private investment funds managed by ADAR1.
How many KZIA ADSs are underlying warrants held by ADAR1-managed funds?
The funds hold Series A and Series B warrants exercisable for 1,615,705 ADSs. Those ADSs are excluded from reported ownership because the warrants are subject to a 4.99% beneficial ownership limitation.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Kazia Therapeutics Ltd
(Name of Issuer)
American Depositary Shares, each representing five-hundred Ordinary Shares
(Title of Class of Securities)
48669G303
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
48669G303
1
Names of Reporting Persons
ADAR1 Capital Management, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
TEXAS
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
967,740.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
967,740.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
967,740.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.2 %
12
Type of Reporting Person (See Instructions)
IA, OO
Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 967,740 American Depositary Shares ("Depositary Shares"), each representing five hundred ordinary shares ("Ordinary Shares"), of Kazia Therapeutics Limited (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC ("ADAR1"). Such securities may be deemed to be indirectly beneficially owned by ADAR1. In addition to the Depositary Shares reported above, certain private investment funds managed by ADAR1 hold Series A and Series B warrants exercisable for 1,615,705 Depositary Shares. The Depositary Shares issuable upon exercise of these warrants are excluded from the amounts reported in boxes 6, 8, 9 and 11 because such warrants are subject to 4.99% beneficial ownership limitations determined in relation to the number of Ordinary Shares underlying the Depositary Shares.
The percentage in box 11 is based on 15,548,878 Depositary Shares outstanding (representing 7,774,439,234 Ordinary Shares; each Depositary Share represents 500 Ordinary Shares) of the Issuer, as referenced in the Issuer's prospectus supplement dated August 28, 2026, filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on August 31, 2026.
SCHEDULE 13G
CUSIP Number(s):
48669G303
1
Names of Reporting Persons
Daniel Schneeberger
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
SWITZERLAND
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
967,740.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
967,740.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
967,740.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
6.2 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 967,740 American Depositary Shares ("Depositary Shares"), each representing five hundred ordinary shares ("Ordinary Shares"), of Kazia Therapeutics Limited (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC ("ADAR1"). Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1. In addition to the Depositary Shares reported above, certain private investment funds managed by ADAR1 hold Series A and Series B warrants exercisable for 1,615,705 Depositary Shares. The Depositary Shares issuable upon exercise of these warrants are excluded from the amounts reported in boxes 6, 8, 9 and 11 because such warrants are subject to 4.99% beneficial ownership limitations determined in relation to the number of Ordinary Shares underlying the Depositary Shares.
The percentage in box 11 is based on 15,548,878 Depositary Shares outstanding (representing 7,774,439,234 Ordinary Shares; each Depositary Share represents 500 Ordinary Shares) of the Issuer, as referenced in the Issuer's prospectus supplement dated August 28, 2026, filed pursuant to Rule 424(b)(5) with the Securities and Exchange Commission on August 31, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Kazia Therapeutics Ltd
(b)
Address of issuer's principal executive offices:
Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW, C3 2000
Item 2.
(a)
Name of person filing:
This Schedule is being filed on behalf of each of the following persons (each, a "Reporting Person" and collectively, the "Reporting Persons"):
(i) ADAR1 Capital Management, LLC ("ADAR1 Capital Management"); and
(ii) Daniel Schneeberger ("Mr. Schneeberger").
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is 3503 Wild Cherry Drive, Building 9, Austin, Texas 78738.
(c)
Citizenship:
(i) ADAR1 Capital Management is a Texas limited liability company; and
(ii) Mr. Schneeberger is a citizen of Switzerland.
(d)
Title of class of securities:
American Depositary Shares, each representing five-hundred Ordinary Shares
(e)
CUSIP Number(s):
48669G303
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(b)
Percent of class:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(ii) Shared power to vote or to direct the vote:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(iii) Sole power to dispose or to direct the disposition of:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
(iv) Shared power to dispose or to direct the disposition of:
The information contained on the cover pages of this Schedule 13G is incorporated herein by reference.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
Mr. Schneeberger is filing this Schedule 13G as a control person in respect of shares beneficially owned by ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E).
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.